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The history of thyroid pathology has evolved overmany years as pathologists identified characteristic
morphologic features of tumors that were associated with
distinct clinical behaviors. In the 1960s, thyroid tumor clas-
sification was relatively simple. Papillary thyroid carcinoma
(PTC) was recognized as a tumor with papillary architecture
and as a relatively indolent but locally invasive malignancy
that had a predominant tendency to spread to regional lymph
nodes. Conversely, follicular thyroid carcinoma (FTC) was a
follicular-patterned tumor that was usually expansile and
encapsulated but invaded through its capsule and into blood
vessels to spread hematogenously; carcinomas with mixed
papillary and follicular architectures were determined to
behave more like PTCs.
Beginning in the 1970s, endocrine pathologists realized that
this simplicity did not capture the full complexity of the situ-
ation. Following seminal studies of Lindsay (1), the important
recognition in 1977 of the value of nuclear features to predict
PTC-like behavior in follicular-patterned tumors gave rise to a
new entity: the follicular variant of PTC (FVPTC) (2,3).
In 2014, we face a very complex classification of thyroid
carcinomas with multiple variants of every major tumor type
(4). As in every field, there are pathologists who are ‘‘split-
ters’’ and subclassify every variant, and there are ‘‘lumpers’’
who prefer to consolidate lesions with similar behaviors and
only recognize as important those variants that have clinical
significance. While every variant of thyroid cancer has its
proponents, there comes a point where differences lose their
value by complicating the ability to compare data and thus
contribute to appropriate patient care.
Molecular classifications of cancers allow pathologists to
step back and recognize the biological basis for similarities
and differences in the various subtypes of malignancies. The
recent publication of an integrated genomic characterization
of papillary thyroid carcinoma by The Cancer Genome Atlas
(TCGA) Research Network has done exactly that for the most
common endocrine malignancy—PTC (5).
One of the most important outcomes of this study is the
validation of morphology as a reflection of tumor biology and
an important parameter in determining tumor behavior. The
classification of PTCs into BRAFV600E-like and RAS-like
tumors with strikingly distinct genomic features has provided
validation of the conventional distinction between classical
PTCs and FVPTCs. While the former generally fall into the
BRAFV600E-like category, follicular architecture and rela-
tively subtle nuclear atypia are the hallmark of the RAS-like
lesions that are classified as FVPTC. The thyroid differenti-
ation scores (TDS) that were determined based on expression
of thyroid function genes in this integrated analysis support
the clinical evidence that FVPTC displays a gene expression
profile that resembles normal thyroid, as we would expect
based on its morphology, whereas classical and tall cell PTCs,
while still falling within the category of well-differentiated
thyroid cancers, are BRAFV600E-like and show relatively less
evidence of thyroid differentiation with lower expression
levels of TDS genes.
What the TCGA findings do not address is the distinction
between FVPTC and FTC. Although not specifically in-
cluded in the analysis, FTCs are known to harbor RAS mu-
tations and have frequent copy number changes (6,7). The
common detection of the same RAS mutations and arm-level
copy number changes in FVPTC raises the question as to
whether FTC and FVPTC are truly distinct entities and, im-
portantly, whether the distinction is of biologic and clinical
relevance. Moreover, it is almost certain that some of the 99
FVPTCs included in the study would have been diagnosed as
FTCs by some experts, since this area is the subject of one of
the controversial disputes in pathology (8,9). There is es-
sentially no consensus regarding the nuclear features seen in
FVPTC, that is, how florid nuclear atypia must be or how
many atypical nuclei in a follicular lesion are required to
classify a neoplasm as FVPTC. Nevertheless, the fact re-
mains that thyroid tumors that show complete follicular ar-
chitecture and grow as expansile and often encapsulated
masses harbor RAS or RAS-like mutations as the hallmark of
their genetic signature.
Pathologists must now reconsider the value of separating
these nearly identical lesions into FTC and FVPTC. We
propose that the time has come, based onmolecular evidence,
to do away with the verbose and often confusing terminology
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‘‘follicular variant of papillary thyroid carcinoma.’’ But what
will the implications of this reclassification be?
The implications for PTC will be clear—the terminology
will remain applicable to all thyroid carcinomas that have any
form of papillary architecture (except for the rare benign
papillary lesions known as ‘‘papillary hyperplastic nodules’’
or ‘‘follicular adenomas with papillary hyperplastic features’’
that lack any of the nuclear atypia of PTC and are generally
functioning nodules). This classification will be used for all
infiltrative lesions, despite follicular architecture that may
predominate (10). These BRAFV600E-like lesions will be ex-
pected to behave like classical or tall-cell PTC. However,
beyond this separation, the TCGA study illustrates the ge-
netic heterogeneity present in these ‘‘true’’ PTCs that reflects
other genetic changes beyond the common driving alterations
and/or altered miRNA expression. Much of this genetic
heterogeneity is reflected in tumor morphology (e.g., tall
cell), and it will require additional validation efforts—
morphological and molecular—to establish the best way to
uncover these differences in pathology practice. Such work is
already underway.
The implications for follicular-patterned lesions and FTC
are more onerous. As we recognize that expansile thyroid
neoplasms with follicular architecture are all RAS-like tumors
with high TDS, the distinction between benign, malignant, and
aggressive neoplasms remains a challenge. The true predictor
of malignant potential in follicular-patterned tumors remains
unclear, but may well be one or several of the candidates:
nuclear features that were the foundation of FVPTC, the RAS
gene mutation signature, capsular invasion, angioinvasion, or
some combination of these. While as pathologists we have
been rewarded with the validation of papillary-patterned PTC
by genomics, we remain humbled by our lack of consensus
concerning the nuclear atypia and features of these follicular-
patterned tumors. We must also admit our limitations in
identifying capsular invasion based on sampling of capsular
tissue for examination, since no tumor can undergo complete
capsular examination using our routine histologic approaches.
Even the criteria for assessing angioinvasion are inconsistent
and controversial (11), and as with the capsule of these tumors,
there is noway to ensure thorough evaluation of every relevant
vessel using histology. Those of us following patients who
have developed metastatic carcinoma after the diagnosis of
follicular adenoma have studied those tumors carefully. While
we often can agree retrospectively that there was nuclear
atypia and/or evidence of invasion, there is still difficulty in the
pathology community accepting those features prospectively
in new cases.
The TCGA study provides us with the opportunity to
simplify thyroid cancer classification by putting an end to the
complexity of FVPTC. Instead, we should refocus our efforts
to move forward with meaningful studies of the complex area
of follicular thyroid neoplasia. Ideally, large-scale pan-
genomic studies like TCGA of benign and malignant follic-
ular tumors will address this problem.
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